Ketul R Chaudhary

List of Publications by Year in Descending Order

22 papers	675 citations	15 h-index	25 g-index
26 ext. papers	763 ext. citations	6.8 avg, IF	3.74 L-index

#	Paper	IF	Citations
22	Penetrance of Severe Pulmonary Arterial Hypertension in Response to Vascular Endothelial Growth Factor Receptor 2 Blockade in a Genetically Prone Rat Model Is Reduced by Female Sex. *Journal of the American Heart Association*, **2021**, 10, e019488	6	5
21	The Adult Sprague-Dawley Sugen-Hypoxia Rat Is Still "the One:" A Model of Group 1 Pulmonary Hypertension: Reply to Le Cras and Abman. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 621-624	10.2	4
20	Optimizing imaging of the rat pulmonary microvasculature by micro-computed tomography. *Pulmonary Circulation*, **2019**, 9, 2045894019883613	2.7	5
19	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. *Circulation Research*, **2019**, 124, 1551-1567	15.7	24
18	Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1447-1450	10.2	7
17	Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure. *Cardiovascular Research*, **2019**, 115, 788-799	9.9	19
16	Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling. *British Journal of Pharmacology*, **2018**, 175, 3976-3989	8.6	13
15	Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse?. *Circulation Research*, **2017**, 120, 1237-1239	15.7	23
14	Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 461-8	5.7	61
13	Fatty Acids and Cardiac Ischemia Reperfusion Injury **2016**, 39-83		1
12	Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. *Prostaglandins and Other Lipid Mediators*, **2013**, 104-105, 8-17	3.7	31
11	Bioactive Compounds in Heart Disease **2013**, 431-442		2
10	Effect of ischemia reperfusion injury and epoxyeicosatrienoic acids on caveolin expression in mouse myocardium. *Journal of Cardiovascular Pharmacology*, **2013**, 61, 258-63	3.1	18
9	Role of PI3K and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection. *Journal of Molecular and Cellular Cardiology*, **2012**, 53, 43-52	5.8	33
8	Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress. *Canadian Journal of Physiology and Pharmacology*, **2012**, 90, 811-23	2.4	35
7	Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. *British Journal of Pharmacology*, **2011**, 162, 897-907	8.6	56
6	Mitochondria and the aging heart. *Journal of Geriatric Cardiology*, **2011**, 8, 159-67	1.7	42

5	Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. *Journal of Cardiovascular Pharmacology*, **2010**, 55, 67-73	3.1	49
4	Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. *Cardiovascular Research*, **2009**, 83, 362-70	9.9	36
3	Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 297, H37-46	5.2	74
2	Cytochrome P450 enzymes and the heart. *IUBMB Life*, **2009**, 61, 954-60	4.7	58
1	Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 867-75	5.8	70